STOCK TITAN
  1. Home
  2. Sec-filings
  3. AEON
  4. [Form 4] AEON Biopharma, Inc. Insider Trading Activity

AEON Biopharma (AEON) grants 222,684 RSUs to director Palmisano

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

PALMISANO ROBERT J reported acquisition or exercise transactions in this Form 4 filing.

AEON Biopharma director Robert J. Palmisano received an award of 222,684 restricted stock units (RSUs) of Class A Common Stock on June 17, 2026. The RSUs vest in full on the earlier of the one-year anniversary of the grant date or the 2027 annual stockholders’ meeting, subject to continued service. Following this grant, his direct holdings total 258,705 shares.

Positive

  • None.

Negative

  • None.
Insider PALMISANO ROBERT J
Role null
Type Security Shares Price Value
Grant/Award Class A Common Stock 222,684 $0.00 --
Holdings After Transaction: Class A Common Stock — 258,705 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSU grant size 222,684 RSUs Award of Class A Common Stock RSUs on June 17, 2026
Post-grant holdings 258,705 shares Total direct Class A Common Stock after transaction
Grant price per share $0.0000 per share Reported transaction price for RSU grant
restricted stock units financial
"Represents an award of restricted stock units ("RSUs") granted on June 17, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
vest in full financial
"The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary"
annual meeting of the Company's stockholders financial
"the date of the 2027 annual meeting of the Company's stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
PALMISANO ROBERT J
(Last)(First)(Middle)
C/O AEON BIOPHARMA, INC.
5 PARK PLAZA, SUITE 1750
(Street)
IRVINE CALIFORNIA 92614
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
AEON Biopharma, Inc. [ AEON ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Class A Common Stock(1)06/17/2026A222,684A$0(1)258,705D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents an award of restricted stock units ("RSUs") granted on June 17, 2026 (the "Grant Date"). The RSUs vest in full on the earlier to occur of (i) the one (1) year anniversary of the Grant Date and (ii) the date of the 2027 annual meeting of the Company's stockholders, subject to continued service through the applicable vesting date.
/s/ Alexander Wilson, as Attorney-in-Fact, for Robert J. Palmisano06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did AEON Biopharma (AEON) director Robert J. Palmisano receive in this Form 4?

He received an award of 222,684 restricted stock units of Class A Common Stock. These RSUs represent a stock-based compensation grant reported as an acquisition, not an open‑market purchase or sale.

How and when do Robert J. Palmisano’s new AEON RSUs vest?

The 222,684 RSUs vest in full on the earlier of the one‑year anniversary of June 17, 2026, or the 2027 annual stockholders’ meeting. Vesting requires that he continue serving through the applicable vesting date.

Is this AEON Biopharma Form 4 a stock purchase or a compensation grant?

It is a compensation-related grant of restricted stock units reported under transaction code A. The RSUs were awarded at no cash price per share, rather than acquired through an open‑market purchase.

How many AEON Biopharma shares does Robert J. Palmisano hold after this RSU grant?

After the 222,684 RSU award, his total reported direct holdings are 258,705 shares of Class A Common Stock. This figure reflects his position immediately following the reported transaction.

Does this AEON Form 4 involve any derivative securities or option exercises?

No, the filing reports only a grant of restricted stock units as non‑derivative Class A Common Stock. There are no option exercises, conversions, or other derivative transactions shown in the derivative summary.